Adhera Therapeutics Inc

OTC: ATRX · Healthcare · Biotechnology

PublicHQ Baton Rouge, LA · East Baton RougeCIK 0000737207Reports USD

#986 of 1,418 Healthcare companies by revenuetop-decile growth

EA Score

——

FH —DQ 10GM —SS 34

v0.1 · 25/100 weight · pillars only

↑ listing tenure, revenue growth (YoY) · ↓ balance-sheet leverage, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$2.1M

Employees

as of 2026-08-31

Market cap

$722

as of 2026-08-31

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$252.0k$252.0k2019

Net income-$2.1M-$2.1M2022

Operating income-$1.6M-$1.6M2022

Total assets$79.0k$79.0k2022

Liabilities$22.3M$22.3M2022

Equity-$22.2M-$22.2M2022

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Adhera Therapeutics Inc’s revenue?

Adhera Therapeutics Inc booked $252.0k in FY2019 revenue, growing 231% year over year — faster than 90% of Healthcare companies we track, at a -838.9% net margin.

Peers · Healthcare

NewCardio, Inc.——Savara Inc.50D Nexteligent Holdings, Inc.46D Bluejay Diagnostics, Inc.33D Envoy Medical, Inc.33D Wellness Center USA, Inc.——

Neighbors

East Baton Rouge →

Lamar Advertising Company$2.3B58C Business First Bancshares, Inc.$10.7M59C Investar Holding Corporation——Vartech Systems Inc.——

Key facts

CEODavid A. Battat

SectorHealthcare

IndustryBiotechnology

HeadquartersBaton Rouge, LA

ExchangeOTC: ATRX

Employees2

IPO date1993-12-07

Latest filings

8-K2024-01-18 8-K2024-01-16 8-K2023-11-29 10-Q2023-11-20 8-K2023-10-12 10-Q2023-08-21 8-K2023-06-29 10-Q2023-05-22

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.